These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 1710837)

  • 1. Synergism between tissue-type plasminogen activator and a genetically engineered variant lacking the finger domain, the growth factor domain and the first kringle domain.
    Mattson C; Wikström K; Sterky C; Pohl G
    Thromb Haemost; 1991 Mar; 65(3):286-90. PubMed ID: 1710837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant variants of tissue-type plasminogen activator containing amino acid substitutions in the fibronectin finger-like domain and the kringle 1 domain.
    Yahara H; Matsumoto K; Maruyama H; Nagaoka T; Ikenaka Y; Yajima K; Fukao H; Ueshima S; Matsuo O
    Thromb Haemost; 1994 Dec; 72(6):893-9. PubMed ID: 7740460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombolytic properties in a rabbit jugular vein thrombosis model of a tissue-type plasminogen activator mutant lacking the growth factor--and kringle one-domains.
    Emeis JJ; Verheijen JH
    Arzneimittelforschung; 1992 Mar; 42(3):358-62. PubMed ID: 1497699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of human tissue-type plasminogen activator variants with amino acid mutations in the kringle 1 domain.
    Ikenaka Y; Yajima K; Yahara H; Maruyama H; Matsumoto K; Okada K; Ueshima S; Matsuo O
    Blood Coagul Fibrinolysis; 1992 Aug; 3(4):381-7. PubMed ID: 1330023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
    Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J
    Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
    Collen D; De Cock F; Demarsin E; Lijnen HR; Stump DC
    Thromb Haemost; 1986 Aug; 56(1):35-9. PubMed ID: 3095946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potentiation by Lys-plasminogen of clot lysis by single or two chain urokinase-type plasminogen activator or tissue-type plasminogen activator.
    Watahiki Y; Scully MF; Ellis V; Kakkar VV
    Thromb Haemost; 1989 Jun; 61(3):502-6. PubMed ID: 2508259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of the finger domain of tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor 1 (PAI-1) in initiation and progression of thrombolysis.
    Stringer HA; van Swieten P; Horrevoets AJ; Smilde A; Pannekoek H
    Thromb Haemost; 1994 Dec; 72(6):900-5. PubMed ID: 7740461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of domain deletion and/or duplication mutants of a recombinant chimera of tissue-type plasminogen activator and urokinase-type plasminogen activator (rt-PA/u-PA).
    Nelles L; Lijnen HR; Van Nuffelen A; Demarsin E; Collen D
    Thromb Haemost; 1990 Aug; 64(1):53-60. PubMed ID: 2148847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibrin affinity and clearance of t-PA deletion and substitution analogues.
    Johannessen M; Diness V; Pingel K; Petersen LC; Rao D; Lioubin P; O'Hara P; Mulvihill E
    Thromb Haemost; 1990 Feb; 63(1):54-9. PubMed ID: 2111048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant variants of tissue-type plasminogen activator containing amino acid substitutions in the finger domain.
    Yahara H; Matsumoto K; Maruyama H; Nagaoka T; Ikenaka Y; Yajima K; Fukao H; Ueshima S; Matsuo O
    Thromb Haemost; 1992 Dec; 68(6):672-7. PubMed ID: 1287881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetic characterization of tissue-type plasminogen activator (t-PA) and t-PA deletion mutants.
    de Vries C; Veerman H; Nesheim ME; Pannekoek H
    Thromb Haemost; 1991 Mar; 65(3):280-5. PubMed ID: 1904654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site.
    Colucci M; Cavallo LG; Agnelli G; Mele A; Bürgi R; Heim J; Semeraro N
    Thromb Haemost; 1993 May; 69(5):466-72. PubMed ID: 8391727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A bleeding model in rabbits demonstrate fresh clot selectivity for a genetically engineered variant of tissue-type plasminogen activator and for streptokinase.
    Wikström K; Mattsson C; Pohl G
    Thromb Res; 1993 May; 70(3):217-24. PubMed ID: 8392227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombolytic and pharmacokinetic properties of human tissue-type plasminogen activator variants, obtained by deletion and/or duplication of structural/functional domains, in a hamster pulmonary embolism model.
    Collen D; Lijnen HR; Vanlinthout I; Kieckens L; Nelles L; Stassen JM
    Thromb Haemost; 1991 Feb; 65(2):174-80. PubMed ID: 1905070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitor-resistant tissue-type plasminogen activator: an improved thrombolytic agent in vitro.
    Shohet RV; Spitzer S; Madison EL; Bassel-Duby R; Gething MJ; Sambrook JF
    Thromb Haemost; 1994 Jan; 71(1):124-8. PubMed ID: 8165630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A hybrid plasminogen activator binds to the u-PA receptor and has a reduced thrombolytic potency in vivo.
    Asselbergs FA; Bürgi R; Hamerman J; Heim J; van Oostrum J; Agnelli G
    Thromb Haemost; 1993 Jan; 69(1):50-5. PubMed ID: 8383359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic effect on thrombolysis of sequential infusion of tissue-type plasminogen activator (t-PA) single-chain urokinase-type plasminogen activator (scu-PA) and urokinase in the rabbit jugular vein thrombosis model.
    Collen D; Stassen JM; De Cock F
    Thromb Haemost; 1987 Oct; 58(3):943-6. PubMed ID: 3124288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of the fast-acting inhibitor of plasminogen activator on in vivo thrombolysis induced by tissue-type plasminogen activator in rabbits. Interference of tissue-derived components.
    Colucci M; Paramo JA; Stassen JM; Collen D
    J Clin Invest; 1986 Jul; 78(1):138-44. PubMed ID: 3088040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure and function of human tissue-type plasminogen activator (t-PA).
    van Zonneveld AJ; Veerman H; MacDonald ME; van Mourik JA; Pannekoek H
    J Cell Biochem; 1986; 32(3):169-78. PubMed ID: 3097031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.